Faron Pharmaceuticals doses first patient in Phase 1/2 BLAZE trial of bexmarilimab plus Bristol Myers’ Opdivo in PD-1-resistant solid tumors

By Public Technologies
  • Faron Pharmaceuticals Oyj dosed the first patient in the Phase 1/2 BLAZE investigator-initiated trial of bexmarilimab with nivolumab.
  • Results have not been presented; the trial is designed to generate future safety and anti-tumor activity data in anti-PD-1-resistant NSCLC and melanoma.
  • The study targets patients whose disease progressed after prior immunotherapy, testing whether the combination can restore sensitivity to checkpoint inhibition.
  • The regimen uses an initial bexmarilimab run-in before combination dosing, supporting Faron’s strategy to expand into PD-1 combination treatment settings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faron Pharmaceuticals Oyj published the original content used to generate this news brief on October 01, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.